MarketsandMarkets

ImmunoBio Series 2024 - West Coast Edition

08th - 09th February 2024

Double Tree by Hilton, San Diego - Mission Valley | 7450 Hazard Centre Drive San Diego, CA

Bridging Science, Innovation, and Health for a Better Tomorrow

MarketsandMarkets presents the Immunobio Series, an extraordinary trio of conferences taking place on 8-9 February 2024 in San Diego, California.

MarketsandMarkets 9th Annual Biomarker and Companion Diagnostics Conference:

Dive into the world of biomarkers at our flagship event, uniting experts and industry leaders to drive innovation in healthcare, diagnostics, and personalized medicine. Explore groundbreaking research and applications, fostering collaboration and knowledge sharing.

MarketsandMarkets 6th Annual Next Gen Microbiome and Probiotics Conference:

Discover the future of microbiome therapies and probiotics. Engage with professionals from diverse sectors to explore microbial innovation, regulatory pathways, and the vital microbiome-probiotics connection. Delve into cutting-edge research and strategies for successful commercialization.

MarketsandMarkets Next Gen Immuno-Oncology Conference:

Explore the forefront of cancer treatment at our inaugural Immuno-Oncology Conference. Join researchers and industry experts to discuss advancements in ADCs, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors. Participate in discussions, share insights, and shape the future of immuno-oncology.

Tag Line
Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics. Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects. Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation. Clinical Applications of Biomarkers: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches. Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms. Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.
Tag Line
Exploring the Function of the Gut Microbiome and Modulation of Immune Cells Role of human skin microbiome in precision health Modulating the GI Microbiome with Live Biotherapeutic Product to Enhance Efficacy of Cancer Immunotherapy Oral-Systemic Microbiome Connection and its Modulation Modulating the Vaginal Microbiome for Women’s Health and Fertility Mechanisms of Oncobiotic LBP Candidate in Enhancing Cancer Immunotherapy Microbiome as a science and its clinical applications- skin, gut & women’s health Prebiotics, Probiotics and Postbiotics Treating Clostridioides difficile: Microbiota-based Live Biotherapeutic Products to Provide the Answer  Microbiome’s Role in Cancer
Tag Line
Preclinical and Translational Immuno-Oncology Developments Next Gen Antibodies and Targeted Therapies Immune Checkpoint Inhibitors and Combination Therapies Tumor Microenvironment and Cancer Biomarkers CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy Cancer Vaccines and Cancer Microbiome Personalizing Cancer Treatment- Challenges and Opportunities

Join us for this transformative event, where innovation meets collaboration, shaping the future of healthcare and biotechnology. MARKETSANDMARKETS IMMUNOBIO SERIES 2024- SAN DIEGO, CALIFORNIA

CO-LOCATED CONFERENCES

MarketsandMarkets Next-Gen Immuno-Oncology Conference - West Coast Edition
6th Annual MarketsandMarkets Next-Gen Microbiome and Probiotics Conference
9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference - West Coast Edition

WHAT TO EXPECT

  • CUTTING-EDGE INSIGHTS: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
  • MULTIDISCIPLINARY LEARNING: Gain a comprehensive understanding of microbiome and probiotics research, exploring diverse topics and practical applications across healthcare, biotechnology, and food production.
  • INNOVATIVE IMMUNOTHERAPY: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
  • PROFESSIONAL DEVELOPMENT: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for microbiome and probiotics research.
  • PRACTICAL APPLICATIONS: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
  • PERSONAL AND INDUSTRY GROWTH: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research, microbiome studies, and immunotherapy.

Immerse yourself in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

Steam A - Biomarker and Companion Diagnostics Conference

Stream B - Next Gen Microbiome and Probiotics Conference

Stream C- Next Gen Immuno-Oncology Conference

  1. Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics.
  2. Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects.
  3. Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation.
  4. Clinical Applications of Biomarker: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers
  5. Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches.
  6. Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms.
  7. Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.

 

  1. Exploring the Function of the Gut Microbiome and Modulation of Immune Cells
  2. Role of human skin microbiome in precision health
  3. Modulating the GI Microbiome with Live Biotherapeutic Product to Enhance Efficacy of Cancer Immunotherapy
  4. Oral-Systemic Microbiome Connection and its Modulation
  5. Modulating the Vaginal Microbiome for Women’s Health and Fertility
  6. Mechanisms of Oncobiotic LBP candidate in Enhancing Cancer Immunotherapy
  7. Microbiome as a science and its clinical applications- skin, gut & women’s health
  8. Prebiotics, Probiotics and Postbiotics
  9. Treating Clostridioides difficile: Microbiota-based Live Biotherapeutic Products to Provide the Answer
  10. Microbiome’s role in Cancer

 

  1. Preclinical and Translational Immuno-Oncology Developments
  2. Next Gen Antibodies and Targeted Therapies
  3. Immune Checkpoint Inhibitors and Combination Therapies
  4. Tumor Microenvironment and Cancer Biomarkers
  5. CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
  6. Cancer Vaccines and Cancer Microbiome
  7. Personalizing Cancer Treatment- Challenges and Opportunities

 

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

Jim Kean

Jim Kean, Chief Executive Officer, Molecular You

08:55 - 09:00

BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION

Keynote Presentation : Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

09:00 - 09:30

Spatial Analysis in Ulcerative Colitis and Crohn’s Disease

Jiangwei Zhang

Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb

09:30 - 10:00

Development of Methylation and Mutation Panel for Colorectal Cancer

Collin Hidzik

Collin Hidzik, Scientist in product and business development , EpigenDx

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Next Gen Proteomics identified protein signatures for early pan cancer detection and stratification

Kathy Nevola

Kathy Nevola, Data Scientist, Olink

11:15 - 11:45

Flow cytometry for biomarker development, clinical trial assays, MRD, and CDx

Scott J. Bornheimer

Scott J. Bornheimer, Associate Director, Medical & Scientific Affairs, BD Biosciences

11:45 - 12:15

AI and Multimoodal Biomarkers for Personalized Pain Medicine

Carl Saab

Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic

12:15 - 12:45

Identification of cancer cell surface target for antibody drug conjugate development.

Ginette Serrero

Ginette Serrero, Chief Executive Officer, A&G Pharmaceutical, Inc. | Precision Antibody

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Role of biomarkers in personalized medicine Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease.

Matteo D’Antonio

Matteo D’Antonio, Assistant Professor, University of California, San Diego

14:15 - 14:45

Innovative oncology liquid biopsy testing in global markets, from lab testing to CDx

Myles A. Walsh

Myles A. Walsh, Director of Business Development, Predicine

14:45 - 15:15

Microbial Marvels: Unleashing Targeted Drug Discovery with Pragma Bios Innovative Approach to Disease-Associated Small Molecules and Novel Biomarkers

Kareem Barghouti

Kareem Barghouti, CEO, Pragma Bio

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

AI-powered multi-omic health analytics

Jim Kean

Jim Kean, Chief Executive Officer, Molecular You

16:30 - 17:00

Closing Remarks from the Chairperson

17:00 - 17:30

Drinks, Reception & Networking

17:30 - 17:30

Opening Remarks from the Chairperson

 Julius Goepp

Julius Goepp, CEO, Evimero

08:55 - 09:00

UNVEILING TOMORROW’S HEALTH WITH NEW MICROBIOME FINDINGS

Keynote Presentation : An Accurate Cost Effective Long Read Solution Using Short Read NGS Platforms for Microbiome Research and Discovery.

Ming Lei

Ming Lei, President and CEO, Universal Sequencing Technology

09:00 - 09:30

Taxonomy- and Disease Agnostic Approach to Microbiome Therapeutics

 Julius Goepp

Julius Goepp, CEO, Evimero

09:30 - 10:00

Development of human primary cell-culture derived mucus to support microbiome research

Niki Heinz

Niki Heinz, Sr. Director of Business Development, , Altis Biosystems

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Oral-Systemic Microbiome Connection and its Modulation

 Emily Stein

Emily Stein, CEO, Primal Health Inc.

11:15 - 11:45

What is in Your Bottle?

Dana Buckman

Dana Buckman, CEO, BioForm Solutions

11:45 - 12:15

Biocalorimetry, the science behind the calScreener™, is revolutionizing the way companies approach the development of probiotics. This technology simplifies the study of complex interactions, conserves valuable time and resources in screening, and can be instrumental in ensuring product safety and efficacy. The calScreener™ has demonstrated high value in media optimization for probiotic production, and providing phenotypic readouts in opaque and complex growth media. Its key benefits include rapid analysis, non-destructive assay, and the ability to run any type of media. It offers direct metabolism measurement from single and multi-species cultures, and activity yield, setting a new standard in the field.

Katrin Beilharz

Katrin Beilharz, Technical Marketing Specialist, Symcel

12:15 - 12:45

Next-Generation Probiotics Against Enteric Pathogen Infection and Chronic Inflammatory Disease

Arun K. Bhunia

Arun K. Bhunia, Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

REVOLUTIONIZING WELLNESS – EXPLORING THE FUTURE OF MICROBIOME AND PROBIOTICS

How Lifestyle and Life Stages affect Gut Microbiota and the power of Biotics.

Miguel Freitas

Miguel Freitas, Vice President - Scientific Affairs, Danone

14:15 - 14:45

Effect of Back to Health - An Evolutionary Biology Perspective on the Skin Microbiome

Larry Weiss

Larry Weiss, Chief Executive Officer and Founder, Symbiome

14:45 - 15:15

Working with live probiotics – insights in developing effective skincare products from formulator’s perspective

Maya Ivanjesku

Maya Ivanjesku, Chief Scientific Officer, M2B Pharma

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Synbiotics for Human Health – Opportunities and Challenges

Vandana Sharma

Vandana Sharma, Principal Nutrition Scientist, Pharmavite

16:30 - 17:00

Closing Remarks from the Chairperson

 Julius Goepp

Julius Goepp, CEO, Evimero

17:00 - 17:30

Drinks Reception & Networking

17:30 - 17:30

NEW ANTIBODIES DEVELOPMENT AND TUMOR MICRO-ENVIRONMENT

Keynote Presentation – Identification of potential patient selection biomarkers for the treatment of cancer with tivumecirnon (FLX475) in combination with anti-PD-1

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

08:55 - 09:50

Nu.Q® Discover – Quantitative nucleosome biomarker profiling of the tumour microenvironment

Mark Eccleston

Mark Eccleston, Chief Technology Officer, Volition

Eric Ariazi

Eric Ariazi, Distinguished Translational Medicine Scientist, Volition

09:50 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:20

Case Studies Leveraging 20,000 Digitized IO KM Curves– Interactive Analysis and Real-Time Insights at the Forefront of Immuno-Oncology

Bruno Larvol

Bruno Larvol, Founder & CEO, LARVOL

11:20 - 11:55

Advancing the Immuno-Oncology Pipeline with Humanized Mice

Dan Georgess

Dan Georgess, Chief Scientific Officer, TransCure bioServices,

11:55 - 12:30

Veracyte Biopharma Services, your trusted partner for biomarker testing for spatial proteomics, transcriptomics, and genomics

Valerie Balme

Valerie Balme, Associate Director, Business Development, Biopharma

12:30 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:20

BioMice: Preclinical Oncology/Immuno-Oncology Models for Evaluating Novel Therapeutics in Vivo

Jay Zhang

Jay Zhang, Sr. Business Development Manager, Biocytogen

14:20 - 15:00

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

15:00 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Engineered nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects.

A. C. Matin

A. C. Matin, Professor of Microbiology & Immunology, Emeritus , Stanford University School of Medicine

16:30 - 17:00

Closing Remarks from the Chairperson

17:00 - 17:30

Drinks Reception & Networking

17:30 - 17:30

Registration

08:15 - 09:00

Welcome note from MarketsandMarkets

09:00 - 09:05

FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION

Opening Remarks from the Chairperson

Jim Kean

Jim Kean, Chief Executive Officer, Molecular You

09:05 - 09:10

Keynote Presentation Bringing AI to Companion Diagnostics

Ken Bloom

Ken Bloom , Head of Pathology, Nucleai

09:10 - 09:45

The crucial role of biospecimen management in precision medicine

Ayat Alsaraby

Ayat Alsaraby, Sr. Manager, Clinical Biomarker, Repare Therapeutics

09:45 - 10:20

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:20 - 11:05

Opportunities for biomarker development in neuroscience

Pablo Lapuerta

Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.

11:05 - 11:40

Identifying underlying mechanisms of neurological conditions with multi-omic biomarker analysis

Rob Fraser

Rob Fraser, Chief Scientific Officer, Molecular You

11:40 - 12:15

Panel Discussion: Biomarker Revolution: Enhancing Patient Care Across Specialties

Nicole Miller

Nicole Miller, Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx

Ken Bloom

Ken Bloom , Head of Pathology, Nucleai

 Julius Goepp

Julius Goepp, CEO, Evimero

Pablo Lapuerta

Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.

12:15 - 13:00

Lunch and Poster Presentation | One-to-One Networking Meetings

13:00 - 13:30

END OF CONFERENCE

13:30 - 13:30

Opening Remarks from the Chairperson

 Julius Goepp

Julius Goepp, CEO, Evimero

09:05 - 09:10

CULTIVATING WELLNESS: PIONEERING THE FUTURE OF MICROBIOME AND PROBIOTICS

Keynote Presentation: Functional Food & The Microbiome, Mitochondria Axis

Christopher Damman

Christopher Damman, Associate Professor of Gastroenterology, University of Washington

09:10 - 09:45

Implementation of Metaproteomics approaches for characterizing the dynamic metabolic activities in human gut microbiomes.

Robert Hettich

Robert Hettich, Distinguished Research Scientist | Leader-Bioanalytical Mass Spectrometry Group of the Biosciences Division, Oak Ridge National Laboratory

09:45 - 10:20

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:20 - 11:05

Metabolic Characterization of Microbial Communities

Peter Karp

Peter Karp, Technical Director of the Bioinformatics Research Group, , SRI International

11:05 - 11:40

Developing microbiome-powered treatments for chronic skin conditions

 Lada Rasochova

Lada Rasochova, CEO, Dermala

11:40 - 12:15

May the Fiber Be with You: Gut Microbiomes from a remote Amazon village to the undergraduate lab

Kathrine Whiteson

Kathrine Whiteson, Associate Professor, Irvine University of California, Irvine and co-Director, UCI Microbiome

12:15 - 12:45

Panel Discussion: Emerging Technologies in Microbiome & Probiotics

Marina Santiago

Marina Santiago, Director of Strategic Projects, mbiomics

Maya Ivanjesku

Maya Ivanjesku, Chief Scientific Officer, M2B Pharma

Larry Weiss

Larry Weiss, Chief Executive Officer and Founder, Symbiome

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 13:30

END OF CONFERENCE

13:30 - 13:30

Opening Remarks from the Chairperson

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

09:05 - 09:10

PRECLINICAL AND TRANSLATIONAL IMMUNO-ONCOLOGY UPDATES- NEW CHECKPOINTS FOR IO

Rapid discovery and screening of truly human biologics

Wyatt McDonnell

Wyatt McDonnell, Co-Founder, CEO, and Chairman of the Board of Directors, Infinimmune

09:10 - 09:45

Mechanistic insights into PD-1 action-translational and clinical data.

Adil Daud

Adil Daud, Director, Melanoma Program, UCSF Medical Center

09:45 - 10:20

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:20 - 11:05

Spatial Analytics of the TME and Discovering Spatial Biomarkers for Immunotherapy

Arvind Rao

Arvind Rao, Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor

11:05 - 11:40

Developments in car-t and t-cell therapies personalized immunotherapy Preclinical Data for Novel Oncolytic Agent and its Ability to Pair with Immune Checkpoint Blockade

Matt Giacalone

Matt Giacalone, CEO, Vaxiion Therapeutics

11:40 - 12:15

Panel Discussion: Clinical Applications of Biomarkers in Immuno-Oncology, Immunology, Neurology, and Inflammatory Diseases

Jack Chen

Jack Chen, Scientific Director, Immuno-Oncology, Precision Medicine, AbbVie

Rob Fraser

Rob Fraser, Chief Scientific Officer, Molecular You

Wyatt McDonnell

Wyatt McDonnell, Co-Founder, CEO, and Chairman of the Board of Directors, Infinimmune

12:15 - 13:00

Lunch and Poster Presentation | One-to-One Networking Meetings

13:00 - 13:30

END OF CONFERENCE

13:30 - 13:30

SPEAKERS

Christopher Damman

Christopher Damman

Associate Professor of Gastroenterology, University of Washington

Nur Hasan

Nur Hasan

Chief Executive Officer, EzBiome Inc

A. C. Matin

A. C. Matin

Professor of Microbiology & Immunology, Emeritus , Stanford University School of Medicine

 Paul Kassner

Paul Kassner

Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

Dana Buckman

Dana Buckman

CEO, BioForm Solutions

Jim Kean

Jim Kean

Chief Executive Officer, Molecular You

Adil Daud

Adil Daud

Director, Melanoma Program, UCSF Medical Center

Pablo Lapuerta

Pablo Lapuerta

Chief Executive Officer, 4M Therapeutics Inc.

Arun K. Bhunia

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

Maya Ivanjesku

Maya Ivanjesku

Chief Scientific Officer, M2B Pharma

Vandana Sharma

Vandana Sharma

Principal Nutrition Scientist, Pharmavite

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Marina Santiago

Marina Santiago

Director of Strategic Projects, mbiomics

Antonio Gomes

Antonio Gomes

Principal Scientist, Xbiome

Kevin Roelofs

Kevin Roelofs

Principal Consultant, Greenbeard Consulting LLC

Carl Saab

Carl Saab

Professor, Innovation Lead Digital Health, Cleveland Clinic

Robert Hettich

Robert Hettich

Distinguished Research Scientist | Leader-Bioanalytical Mass Spectrometry Group of the Biosciences Division, Oak Ridge National Laboratory

TBA, Senior Representative, Biocytogen

TBA, Senior Representative, Biocytogen

,

Bruno Larvol

Bruno Larvol

Founder & CEO, LARVOL

TBA, Senior Representative, Elucidata

TBA, Senior Representative, Elucidata

Senior Representative, Elucidata

Ginette Serrero

Ginette Serrero

Chief Executive Officer, A&G Pharmaceutical, Inc. | Precision Antibody

Zachery Lewis

Zachery Lewis

Principal Consultant, Lewpine Consulting

Leena Gandhi

Leena Gandhi

Chief Medical Officer, NextPoint Therapeutics, Inc.

Mark Eccleston

Mark Eccleston

Chief Technology Officer, Volition

Rob Fraser

Rob Fraser

Chief Scientific Officer, Molecular You

Ming Lei

Ming Lei

President and CEO, Universal Sequencing Technology

Eric Ariazi

Eric Ariazi

Distinguished Translational Medicine Scientist, Volition

Myles A. Walsh

Myles A. Walsh

Director of Business Development, Predicine

Sahil Khanna

Sahil Khanna

Professor of Medicine, Chair GI Hospital Practice, Associate Program Director Internal Medicine Residency Program, Medical Director Desk and Secretarial Operations, Mayo Clinic

Matt Giacalone

Matt Giacalone

CEO, Vaxiion Therapeutics

Jiangwei Zhang

Jiangwei Zhang

Senior Principal Scientist, Bristol Myers Squibb

Kareem Barghouti

Kareem Barghouti

CEO, Pragma Bio

 Julius Goepp

Julius Goepp

CEO, Evimero

Kathy Nevola

Kathy Nevola

Data Scientist, Olink

Mikael Barmore

Mikael Barmore

VP Biopharma Business Development, Veracyte

Miguel Freitas

Miguel Freitas

Vice President - Scientific Affairs, Danone

Collin Hidzik

Collin Hidzik

Scientist in product and business development , EpigenDx

Jack Chen

Jack Chen

Scientific Director, Immuno-Oncology, Precision Medicine, AbbVie

Matteo D’Antonio

Matteo D’Antonio

Assistant Professor, University of California, San Diego

Larry Weiss

Larry Weiss

Chief Executive Officer and Founder, Symbiome

Kathrine Whiteson

Kathrine Whiteson

Associate Professor, Irvine University of California, Irvine and co-Director, UCI Microbiome

Katrin Beilharz

Katrin Beilharz

Technical Marketing Specialist, Symcel

Arvind Rao

Arvind Rao

Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor

TBA, Senior Representative, Universal Sequencing

TBA, Senior Representative, Universal Sequencing

Senior Representative, Universal Sequencing

Valerie Balme

Valerie Balme

Associate Director, Business Development, Biopharma

Peter Karp

Peter Karp

Technical Director of the Bioinformatics Research Group, , SRI International

Niki Heinz

Niki Heinz

Sr. Director of Business Development, , Altis Biosystems

Jay Zhang

Jay Zhang

Sr. Business Development Manager, Biocytogen

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Double Tree by Hilton, San Diego - Mission Valley | 7450 Hazard Centre Drive San Diego, CA

PAST EVENT GALLERY